ARTV (STOCKS)
Artiva Biotherapeutics, Inc. Common Stock
$7.180000
+0.370000 (+5.43%)
Prev close: $6.810000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Fred Aslan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $179.94M
- Employees
- 105
- P/E (TTM)
- -1.98
- P/B (TTM)
- 1.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.85 | $-0.84 | -0.0071 | -0.84% |
|
Sep 2025 (Q3)
|
$-0.88 | $-0.89 | +0.0074 | +0.83% |
|
Jun 2025 (Q2)
|
$-0.87 | $-0.82 | -0.0472 | -5.74% |
|
Mar 2025 (Q1)
|
$-0.83 | $-0.72 | -0.1053 | -14.53% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $5.95M |
| Operating Expenses | $89.81M |
| Research and Development | $69.54M |
| Other Operating Expenses | $20.27M |
| Operating Income/Loss | -$89.81M |
| Income/Loss From Continuing Operations After Tax | -$83.87M |
| Income/Loss From Continuing Operations Before Tax | -$83.87M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$83.87M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$83.87M |
| Net Income/Loss Available To Common Stockholders, Basic | -$83.87M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.43 |
| Diluted Earnings Per Share | -$3.43 |
| Basic Average Shares | 24,444,057 |
| Diluted Average Shares | 24,444,057 |
| Assets | $130.94M |
| Current Assets | $112.67M |
| Cash | $108.00M |
| Other Current Assets | $4.67M |
| Noncurrent Assets | $18.27M |
| Fixed Assets | $6.62M |
| Other Non-current Assets | $11.66M |
| Liabilities | $20.97M |
| Current Liabilities | $13.09M |
| Accounts Payable | $355.00K |
| Wages | $7.57M |
| Other Current Liabilities | $5.16M |
| Noncurrent Liabilities | $7.88M |
| Equity | $109.97M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $109.97M |
| Liabilities And Equity | $130.94M |
| Net Cash Flow From Operating Activities | -$76.75M |
| Net Cash Flow From Operating Activities, Continuing | -$76.75M |
| Net Cash Flow From Investing Activities | $63.41M |
| Net Cash Flow From Investing Activities, Continuing | $63.41M |
| Net Cash Flow From Financing Activities | $9.00K |
| Net Cash Flow From Financing Activities, Continuing | $9.00K |
| Net Cash Flow | -$13.33M |
| Net Cash Flow, Continuing | -$13.33M |
| Comprehensive Income/Loss | -$83.63M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$83.63M |
| Other Comprehensive Income/Loss | -$83.63M |